Hodgkin lymphoma (HL) is a rare B-cell lymphatic malignancy distinguished by its unique histological, immunophenotypic, and clinical characteristics 1,2 . According to the 2022 Hong Kong Cancer Registry data, HL accounts for ~3% of all haematologica...
Multiple myeloma (MM) is one of the most common haematological malignancies with a global incidence ranging from 0.5 to 5 per 100,000 1 . It is characterised by the monoclonal proliferation of malignant plasma cells in the bone marrow, leading to da...
Multiple myeloma is a clonal plasma cell proliferative disorder that is often diagnosed in individuals aged 65 to 74 years 1 . Notably, the treatment landscape of MM has evolved over the last few years with availability of newer agents and combinati...
ANAGRELIDE SANDOZ® (Anagrelide hydrochloride) NOVARTIS HK Reg. No. HK-68231 Composition: 2 ANAGRELIDE SANDOZ® (anagrelide hydrochloride) is an inhibitor of cyclic AMP phosphodiesterase III. It is available in 0.5 mg hard capsule. Indication:...
TARGRETIN™ (bexarotene) MAIN LIFE HK Reg. No. HK-68294 (04 Jul, 2024) Composition: 1 Targretin™ (bexarotene) is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). Targretin™ is available in c...
Multiple myeloma (MM) is a haematologic malignancy characterised by abnormal clonal plasma cells in the bone marrow with a potential for uncontrolled growth causing destruction, osseous lesion, acute kidney injury (AKI), anaemia, and hypercalcaemia....
Rare diseases typically have a prevalence below 0.05% and constitute around 10,000 diseases, cumulatively affecting over 5% of the global population. Although there is a large unmet need in treatment, the recent advent of gene therapy is beginning t...
Tumour protein 53 (TP53) gene is located on the chromosome 17 that encodes for the p53 protein, which is a tumour suppressor protein with 393 amino acid responsible for regulating cellular stress 1 . Notably, TP53 can be inactivated directly due to ...
COLUMVI (glofitamab-gxbm) ROCHE Indications: COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from foll...
AL Amyloidosis: A Rare but Multifaceted Disease Light chain (AL) amyloidosis is a rare multi-systemic, incurable protein misfolding disorder characterised by plasma cell dyscrasia and abnormal clonal plasma cell proliferation 1 . Immunoglobulin secr...
Adynovate (rurioctocog alfa pegol) Takeda Composition: Adynovate 250 and 500 International Units (IU). Adynovate [rurioctocog alfa pegol, Recombinant Coagulation Factor VIII (rch), PEGylated] is supplied in single-use vials containing nominal poten...
Exkivity® ( mobocertinib ) 1-3 Takeda Mobocertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that selectively inhibits and irreversibly binds to EGFR exon 20 insertion mutations at lower concentrations than Wild type (...
